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ARTICLE
Sex and APOE ε4 genotype modify the Alzheimer’s
disease serum metabolome
Matthias Arnold et al.#
Late-onset Alzheimer’s disease (AD) can, in part, be considered a metabolic disease. Besides
age, female sex and APOE ε4 genotype represent strong risk factors for AD that also give rise
to large metabolic differences. We systematically investigated group-specific metabolic
alterations by conducting stratified association analyses of 139 serum metabolites in 1,517
individuals from the AD Neuroimaging Initiative with AD biomarkers. We observed sub-
stantial sex differences in effects of 15 metabolites with partially overlapping differences for
APOE ε4 status groups. Several group-specific metabolic alterations were not observed in
unstratified analyses using sex and APOE ε4 as covariates. Combined stratification revealed
further subgroup-specific metabolic effects limited to APOE ε4+ females. The observed
metabolic alterations suggest that females experience greater impairment of mitochondrial
energy production than males. Dissecting metabolic heterogeneity in AD pathogenesis can
therefore enable grading the biomedical relevance for specific pathways within specific
subgroups, guiding the way to personalized medicine.
https://doi.org/10.1038/s41467-020-14959-w OPEN
*A full list of authors and their affiliations appears at the end of the paper.
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Female sex is regarded a major risk factor for Alzheimer’sdisease (AD). Of 5.3 million people in the United Statesdiagnosed with AD at age 65 or older, > 60% are women.
The lifetime risk of developing AD at age 45 may be almost
double in females than in males1,2, though the exact role and
magnitude of a sexual dimorphism in predisposition and pro-
gression to AD are controversial3–6. Although age is the strongest
risk factor for late-onset AD (LOAD), the higher life expectancy
of women only partially explains the observed sex difference in
frequency and lifetime risk7. Complexity is added by studies
showing a significant sex difference in effects of the APOE ε4
genotype, the strongest common genetic risk factor for LOAD.
These studies report risk estimates for ε4 carriers being higher in
females, a finding that seems to be additionally dependent on
age8–13. APOE ε4 is also associated with AD biomarkers in a sex-
dependent way with larger risk estimates for women than for
men9,14–17, although these findings have not been fully consistent
across studies16,18. In addition, studies suggest that sex differences
in AD may change during the trajectory of disease19. Overall risk
for mild cognitive impairment (MCI), the prodromal stage of AD,
is higher in males20,21, whereas progression to AD occurs faster in
females, at least partly in APOE ε4-dependent ways3,8,10,19,22,23.
The mechanisms underlying this sex-linked and partly inter-
twined age- and APOE ε4-dependent heterogeneity in AD sus-
ceptibility and severity are only beginning to unravel, calling for
novel approaches to further elucidate molecular sex differences in
AD risk and biomarker profiles.
Interestingly, all three of the aforementioned major AD risk
factors, age, APOE ε4 genotype, and sex, have a profound impact
on metabolism24–30, supporting the view of AD as a metabolic
disease31–33. In recent years, availability of high-throughput
metabolomics techniques, which can measure hundreds of small
biochemical molecules (metabolites) simultaneously, enabled the
study of metabolic imprints of age, genetic variation, and sex very
broadly, covering the entire metabolism: (i) Age-dependent dif-
ferences were observed in levels of phosphatidylcholines (PCs),
sphingomyelins (SMs), acylcarnitines, ceramides, and amino
acids29,34. A panel of 22 independent metabolites explained 59%
of the total variance in chronological age in a large twin popu-
lation cohort. In addition, one of these metabolites, C-glycosyl-
tryptophan, was associated with age-related traits including bone
mineral density, lung30, and kidney function35. (ii) As expected
from APOE’s role in cholesterol and lipid metabolism36,37,
common genetic variants in APOE were associated with blood
cholesterol levels in genome- and metabolome-wide association
studies37,38. In addition, associations with levels of various SMs
were identified39,40. (iii) Analogous to age, sex also affects blood
levels of many metabolites from a broad range of biochemical
pathways. In a healthy elderly population with mostly post-
menopausal women, females showed higher levels of most lipids
except lyso-PCs. Levels of most amino acids including branched
chain amino acids (BCAAs) were higher in males, though glycine
and serine levels were higher in women24,25. Gonzalez-
Covarrubias et al.29 reported sex-specific lipid signatures asso-
ciated with longevity in the Leiden Longevity Study. In women,
higher levels of ether-PC and SM species were associated with
longevity; no significant differences were observed in men. Thus,
based on results from large-scale metabolomics studies, aging
may influence a wider range of metabolites in women than men,
highlighting the need for sex-stratified analyses.
Many metabolites affected by female sex, age, and APOE
genotype (e.g., BCAAs, glutamate, various lipids) appear to be
altered in AD independent of these risk factors39,41,42. In patients
with MCI, alterations in lipid metabolism, lysine metabolism, and
the tricarboxylic acid cycle have been observed43,44. In one of the
largest blood-based metabolomics studies of AD, we identified
metabolic alterations in various stages across the trajectory of the
disease. For instance, higher levels of SMs and PCs were observed
in early stages of AD as defined by abnormal cerebrospinal fluid
(CSF) Aβ1–42 levels, whereas intermediate changes, measured by
CSF total tau, were correlated with increased levels of SMs and
long-chain acylcarnitines45. Changes in brain volume and cog-
nition, usually noted in later stages, were correlated with a shift in
energy substrate utilization from fatty acids to amino acids,
especially BCAAs. Other metabolomics studies have reported
metabolic alterations in AD that support these findings, including
alterations in PCs in AD44,46–48 and sphingolipid transport and
fatty-acid metabolism in MCI/AD compared with cognitively
normal (CN) participants49. Higher blood concentrations of
sphingolipid species were associated with disease progression and
pathological severity at autopsy50. Metabolomics analysis of brain
and blood tissue revealed that bile acids, important regulators of
lipid metabolism and products of human–gut microbiome co-
metabolism, were altered in AD51,52 and associated with brain
glucose metabolism and atrophy as well as CSF Aβ1–42 and p-
tau53. In most of these studies, sex and APOE ε4 genotype were
used as covariates. Thus, these studies may have missed sex-
specific associations between AD and metabolite levels or asso-
ciations with opposite effect directions for the two sexes. Simi-
larly, sex-by-APOE genotype interactions would have been
masked.
Here, we examined the role of sex in the relationship between
metabolic alterations and AD to elucidate possible metabolic
underpinnings for the observed sexual dimorphism in AD sus-
ceptibility and severity. Using metabolomics data from 1517
participants of the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) cohorts, we investigated how sex modifies the associa-
tions of representative A-T-N biomarkers54,55 (A: CSF Aβ1–42
pathology; T: CSF p-tau; N: region of interest (ROI)-based glu-
cose uptake measured by [18F] fluorodeoxyglucose-positron
emission tomography (FDG-PET)) with 139 blood metabolites
using stratified analyses and systematic comparison of effects
between men and women. In downstream analyses, we inspected
sex differences in metabolic effects on AD biomarkers for
dependencies on APOE genotype, both by interaction analysis
and sub-stratification.
Results
Investigating metabolic effect modulation by AD risk factors.
We used CSF biomarkers, FDG-PET imaging, and serum meta-
bolomics data on 139 metabolites to investigate metabolic effects
in relation to sex and AD and their interaction. Of 1517 ADNI
participants, 1082 had CSF Aβ1–42 and p-tau levels and 1143 had
FDG-PET data available (Table 1). We included all individuals
with respective data regardless of diagnostic classification, as we
were interested in these three representatives of the A-T-N AD
biomarker schema54,55 as our main readouts. In this data set,
there was no significant difference in the number of APOE ε4+/−
participants between females and males (PFisher’s exact > 0.3). Of the
three AD biomarkers, only p-tau levels were significantly different
between sexes in covariate-adjusted regression models (PREG=
0.01 after adjustment for three tests) with slightly higher levels in
females.
Previous studies consistently showed widespread metabolic sex
differences, metabolic imprint of genetic variance in the APOE
locus and significant associations between blood metabolites and
AD biomarkers independent of (i.e., adjusted for) sex. The
current study added specific examination of the following central
questions (Supplementary Fig. 1): (i) are peripheral metabolic sex
differences changed owing to presence of (probable) AD?, (ii) are
metabolite associations with A-T-N biomarkers modified by sex?,
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and (iii) is there evidence for APOE ε4 status influencing
metabolite associations with A-T-N biomarkers that show
differences between sexes?
No significant change of metabolic sex differences in AD. We
tested whether sex-associated differences in blood metabolite
levels differ between patients with probable AD, participants with
late MCI, and CN participants in the ADNI cohorts. In the
complete cohort (n= 1517), we found 108 of 139 metabolites to
be significantly associated with sex after multiple testing correc-
tion while adjusting for age, body mass index (BMI), ADNI study
phase, and diagnostic group. Seventy of these associations repli-
cate previous findings in a healthy population using a prior
version of the same metabolomics platform25 that provides
measurements on 92 out of the 108 metabolites identified in
ADNI. All SMs and the majority of PCs were more abundant in
women. The majority of biogenic amines, amino acids, and
acylcarnitines were more abundant in men.
Stratifying participants by diagnostic group revealed that 53 of
the 108 metabolites showing significant sex differences were also
significant in each of the three groups (AD, MCI, CN) alone,
whereas 14 showed no significant difference in any group,
probably owing to lower statistical power after stratification
(Supplementary Data 1 and Supplementary Fig. 2). Significant sex
differences limited to one diagnostic group were found for eight
metabolites (PC aa C34:1, PC ae C34:3, PC ae C36:3, PC ae C36:4,
PC ae C38:5, PC ae C40:5, histidine, C6/C4:1-DC) in patients
with probable AD, for seven metabolites (C0, C3, C9, C18:2,
SDMA, spermidine, t4-OH-Pro) in the MCI group, and for six
metabolites (PC aa C42:0, PC ae C32:1, PC ae C42:3, SM(OH)
C24:1, sarcosine, aspartate) in the CN group. All significant sex
differences found were also significant in the full cohort.
Comparisons of beta estimates for sex between AD and CN
groups showed no significant effect heterogeneity, indicating
reduced power as source for these observed differences
(Supplementary Data 1). The only exception was PC aa C34:1,
which showed significant heterogeneity (PHET= 0.029) between
AD patients compared with CN participants. Notably, in the
larger healthy reference cohort, sex did not significantly affect the
blood level of this metabolite when adjusting for the same study
covariates (i.e., age and BMI)25. In summary, we did not find
evidence for sex differences of blood metabolite levels being
significantly affected by presence of MCI or AD.
Sex modifies associations of metabolites with AD biomarkers.
To investigate whether sex modifies the association between AD
endophenotypes and metabolite concentrations, we tested for
associations of the three representative A-T-N biomarkers, CSF
Aβ1–42 pathology, CSF p-tau levels, and brain glucose uptake
measured via FDG-PET imaging, with concentrations of 139
blood metabolites. We did this in the full data set and separately
in each sex using multivariable linear and logistic regression,
followed by analysis of heterogeneity of effects between sexes.
Table 2 lists the results for all metabolite–phenotype combina-
tions and analyses of sex-by-metabolite interaction effects on A-
T-N biomarkers that fulfilled at least one of the following criteria:
(i) associations significant (at a Bonferroni threshold of PREG <
9.09 × 10−4) in the full cohort; (ii) associations Bonferroni sig-
nificant in one sex; (iii) associations that showed suggestive sig-
nificance (PREG < 0.05) in one sex coupled with significance for
effect heterogeneity between female and male effect estimates.
Results for all metabolites, phenotypes, and statistical models are
provided in Supplementary Data 2. Systematic comparison of
estimated effects in men and women for all metabolites is shown
in Fig. 1. Based on this comparison, we classified metabolite–A-T-
N biomarker associations into homogeneous effects if metabolites
showed very similar effects in their association to the biomarker
for both sexes (i.e., estimated heterogeneity p value PHET > 0.05),
and heterogeneous effects if metabolites showed different effects
in both sexes leading to significant heterogeneity (i.e., estimated
PHET < 0.05) and/or sex–metabolite interaction (for more details
on the concept of effect heterogeneity, see Supplementary Fig. 3).
Effects that were Bonferroni significant in only one sex with
either significant effect heterogeneity between males and females
or significant sex–metabolite interaction were considered sex-
specific.
Homogeneous effects. Metabolites with homogeneous effects lie
on or close to the diagonal going through the first and third
quadrant when plotting the effect estimates in women against
those in men (Fig. 1). We identified eight significant homogenous
metabolite–phenotype associations with A-T-N biomarkers: CSF
Table 1 Characteristics of the 1517 ADNI participants included in this study.
Global data set CN SMC EMCI MCI AD
Nsubjects 1517 362 93 270 490 302
Sex (m/f) 828/689 177/185 39/54 149/121 298/192 165/137
Age 73.72 (+−7.25) 74.61 (+−5.77) 72.34 (+−5.70) 71.26 (+−7.63) 74.03 (+−7.63) 74.79 (+−7.77)
BMI 26.86(+− 4.82) 26.99 (+−4.53) 28.46 (+−6.23) 27.96 (+−5.36) 26.45 (+−4.27) 25.88 (+−4.69)
Education 15.88 (+−2.87) 16.24 (+−2.79) 16.78 (+−2.55) 15.95 (+−2.67) 15.84 (+−2.91) 15.16 (+−3.01)
APOE ε4−/+ 809/708* 261/101 64/29 155/115 224/266 105/197
CSF available 1082* 236 84 245 308 209
Path. Aβ1–42−/+ 407/675 134/102 57/27 122/123 75/233 19/190
CSF Aβ1–42 1052.73 (+
−601.70)
1324.60 (+
−652.13)
1395.01 (+
−618.19)
1172.73 (+
−569.12)
896.35 (+
−501.80)
697.95 (+
−431.49)
CSF p-Tau 27.79 (+−14.56) 22.01 (+−9.19) 21.66 (+−9.14) 24.34 (+−14.03) 30.81 (+−14.94) 36.38 (+−16.07)
FDG-PET available 1143* 247 93 268 318 217
FDG-PET 6.17 (+−0.77) 6.53 (+−0.58) 6.60 (+−0.58) 6.44 (+−0.60) 6.08 (+−0.68) 5.36 (+−0.73)
*Numbers for combined stratification:
APOE ε4− females APOE ε4− males APOE ε4+ females APOE ε4+ males
Total 374 435 315 393
CSF available 267 315 222 278
FDG-PET available 278 337 230 298
CN cognitively normal, SMC subjective memory complaints, EMCI early mild cognitive impairment, MCI mild cognitive impairment, AD probable Alzheimer’s disease, BMI body mass index, APOE ε4−/+
non-carriers and carriers of the APOE ε4 allele, Path. Aβ1–42−/+ participants who have normal and pathological CSF Aβ1–42 levels, respectively.
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Aβ1–42 pathology was significantly associated with levels of three
related ether-containing PCs (PC ae C44:4, PC ae C44:5, PC ae
C44:6). Two of those (PC ae C44:4, PC ae C44:5) were also sig-
nificantly associated with brain glucose uptake (FDG-PET) in
addition to three other PCs (PC aa C32:1, PC aa C32:0, PC ae
C42:4). For p-tau, we found no homogeneous, overall significant
associations. Notably, none of the homogeneous associations
showed any indication of effect heterogeneity between sexes, and
only one reached significance in the sex-stratified analyses: higher
blood levels of the diacyl-PC PC aa C32:1 were associated with
lower glucose uptake in brain in the male stratum alone despite
lower power.
Heterogeneous effects. Metabolites with heterogeneous effects
fall mainly into the second or fourth quadrant (with the exception
of sex-specific effects that are close to one of the axes) when
contrasting the effect estimates for men and women in the plots
for the three A-T-N phenotypes (Fig. 1). We identified 15 asso-
ciations in this category (including three sex-specific effects). For
CSF Aβ1–42, we identified two heterogeneous effects, with
threonine showing a sex-specific effect (see paragraph below)
with greater effect size in males, and valine with a larger effect in
females. Although valine was not significantly associated (PREG=
0.78) with CSF Aβ1–42 pathology in males, in females, it showed a
nominally significant negative association with an estimated
heterogeneity of I2= 49.3%. CSF p-tau had the largest number of
heterogeneous associations: acylcarnitines C5-DC (C6-OH), C8,
C10 (sex-specific), and C2, and the amino acid histidine showed
stronger associations in females, whereas the related ether-
containing PCs, PC ae C36:1 and PC ae C36:2, the amino acids
asparagine and glycine, and one hydroxy-SM (SM (OH) C16:1)
yielded stronger associations in males (all I2 > 50%). Associations
with FDG-PET revealed three heterogeneous effects, with ether-
containing PC ae C40:2 and the acylcarnitine C16:1 (sex-specific)
showing a larger effect in males (I2= 55.3 and 54.1%, respec-
tively), and proline having a larger effect in females (I2= 64.8%).
For seven of the 15 reported heterogeneous effects, the interaction
term (sex × metabolite) in the full cohort was also significantly (at
PREG < 0.05) associated with the respective biomarker.
Sex-specific effects. Metabolites with sex-specific effects fall into
the area close to the x- (male-specific) or y- (female-specific) axes
of the three effect plots for the different A-T-N phenotypes
(Fig. 1). We found three instances of this effect type. Male-specific
effects were seen for threonine with pathological CSF Aβ1–42
(positive association) and C16:1 with FDG-PET (negative asso-
ciation). One female-specific effect was seen: higher levels of the
medium-chain acylcarnitine C10 were associated with higher CSF
p-tau. This association was the strongest seen for p-tau in the full
cohort analysis, yet seems to be driven by female effects only.
Intertwined modulation of metabolite effects by sex and APOE.
Previous reports suggested that the APOE ε4 genotype may exert
AD risk predisposition in a sex-dependent way8–13. To investigate
potential relationships between sex and APOE ε4 status on the
metabolomic level, we selected the 21 metabolites identified in the
previous analyses (Table 2) and performed association analyses
with the three selected A-T-N biomarkers, now stratified by
APOE ε4 status and adjusted for sex. Metabolite effects in APOE
ε4 carriers vs. non-carriers showed effects from all three cate-
gories defined above (Table 3): Homogeneous effects were noted
for the overall significant associations of PC aa C32:1, PC ae
C44:4, PC ae C44:5, PC aa C32:0, and PC ae C42:4 with FDG-
PET. Heterogeneous effects again formed the largest group (n=
11). Proline and glycine showed significantly different effects on
CSF Aβ1–42 pathology for ε4 carriers vs. non-carriers. For FDG-
PET, significant heterogeneity between carriers and non-carriers
was observed for C8, valine, glycine, and proline. Five metabolites
with heterogeneous effects showed APOE ε4 status-specific
effects: PC ae C44:6, PC ae C44:4, PC ae C44:5, and PC ae
C42:4 showed Bonferroni-significant associations with patholo-
gical CSF Aβ1–42 in APOE ε4 carriers; in the case of PC ae C44:6,
PC ae C44:5, and PC ae C44:4, the group-specific effects were
strong enough to drive the signal to overall significance in the full
sample. Acylcarnitine C10 showed a Bonferroni-significant
association with FDG-PET in APOE ε4 non-carriers.
Some metabolic effects are specific to female ε4 carriers. When
we stratified separately by sex and APOE ε4 status, several
Table 2 Association results and heterogeneity estimates for metabolites in relation to A-T-N biomarkers stratified by sex.
Biomarker/
metabolite
Pooled effect Pooled
p value
Effect type Males effect Males
p value
Females effect Females
p value
Sex diff.
statistic
Sex diff.
p value
Sex diff. I² Interaction
p value
Pathological CSF Aβ1–42
PC ae C44:6 0.283 2.58E-04 Homogeneous 0.282 5.96E-03 0.299 1.33E-02 −0.107 9.15E-01 0.000 8.09E-01
PC ae C44:4 0.265 4.57E-04 Homogeneous 0.274 6.29E-03 0.255 3.07E-02 0.119 9.05E-01 0.000 7.83E-01
PC ae C44:5 0.260 5.23E-04 Homogeneous 0.294 3.26E-03 0.214 6.38E-02 0.522 6.01E-01 0.000 4.34E-01
Threonine 0.207 6.72E-03 Male-specific 0.372 8.83E-04 0.070 5.17E-01 1.943 5.20E-02 48.545 4.03E-02
Valine −0.134 1.05E-01 Heterogeneous 0.032 7.80E-01 −0.299 1.50E-02 1.973 4.85E-02 49.322 7.65E-02
CSF p-tau
C10 0.084 4.58E-03 Female-specific 0.014 7.34E-01 0.144 6.07E-04 −2.203 2.76E-02 54.613 2.55E-02
C5−DC (C6−OH) 0.103 2.35E-02 Heterogeneous 0.012 8.52E-01 0.205 2.27E-03 −2.116 3.44E-02 52.740 3.38E-01
C8 0.064 3.42E-02 Heterogeneous 0.003 9.39E-01 0.127 5.11E-03 −2.028 4.26E-02 50.692 5.63E-02
PC ae C36:2 0.056 8.65E-02 Heterogeneous 0.129 4.80E-03 −0.023 6.18E-01 2.355 1.85E-02 57.535 2.16E-02
Histidine −0.034 2.72E-01 Heterogeneous 0.033 4.39E-01 −0.105 1.97E-02 2.237 2.53E-02 55.290 2.42E-02
Asparagine 0.034 2.84E-01 Heterogeneous 0.107 1.66E-02 −0.052 2.32E-01 2.550 1.08E-02 60.788 2.16E-02
SM (OH) C16:1 0.032 3.10E-01 Heterogeneous 0.091 3.36E-02 −0.039 3.99E-01 2.066 3.89E-02 51.592 3.75E-02
Glycine 0.030 3.50E-01 Heterogeneous 0.104 3.94E-02 −0.026 5.23E-01 2.014 4.40E-02 50.346 6.88E-02
PC ae C36:1 0.028 3.68E-01 Heterogeneous 0.088 4.17E-02 −0.041 3.51E-01 2.094 3.62E-02 52.251 3.76E-02
C2 0.015 5.85E-01 Heterogeneous −0.054 1.67E-01 0.089 3.02E-02 −2.527 1.15E-02 60.430 1.39E-02
FDG-PET
PC aa C32:1 −0.127 2.32E-05 Homogeneous −0.140 6.31E-04 −0.110 1.50E-02 −0.499 6.18E-01 0.000 5.53E-01
PC ae C44:4 −0.111 2.27E-04 Homogeneous −0.097 1.80E-02 −0.141 1.84E-03 0.716 4.74E-01 0.000 2.21E-01
PC ae C44:5 −0.105 4.07E-04 Homogeneous −0.112 5.80E-03 −0.111 1.30E-02 −0.021 9.83E-01 0.000 6.02E-01
PC aa C32:0 −0.107 6.85E-04 Homogeneous −0.125 5.67E-03 −0.091 4.25E-02 −0.547 5.84E-01 0.000 7.44E-01
PC ae C42:4 −0.103 8.56E-04 Homogeneous −0.103 1.58E-02 −0.112 1.33E-02 0.156 8.76E-01 0.000 4.48E-01
C16:1 −0.103 9.09E-04 Male-specific −0.165 9.64E-05 −0.029 5.38E-01 −2.179 2.93E-02 54.107 9.94E-02
PC ae C40:2 −0.053 7.82E-02 Heterogeneous −0.119 4.34E-03 0.016 7.15E-01 −2.238 2.52E-02 55.312 5.78E-02
Proline −0.023 4.51E-01 Heterogeneous 0.059 1.77E-01 −0.118 8.18E-03 2.841 4.50E-03 64.801 7.74E-03
Metabolite associations with A-T-N biomarkers that are either Bonferroni-significant in the full sample, in one sex, or show nominal significance both in one sex and for effect heterogeneity or the
sex×metabolite interaction term. Given are regression results for the full sample and both sexes, as well as heterogeneity estimates and the p value for sex×metabolite interactions. Full association results
for all strata are provided in Supplementary Data 2. Sex diff. results from the heterogeneity analysis.
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Fig. 1 Sex-based effect heterogeneity of metabolites in relation to A-T-N biomarkers. Scatter plots showing Z scores of effect estimates of metabolite
associations with A-T-N biomarkers for males (x axis) versus females (y axis). Homogeneous effects (i.e., those with same effect direction and comparable
effect size) are located close to the diagonal, heterogeneous effects are located close to the anti-diagonal, and sex-specific effects are located close to the x
axis for male-specific and y axis for female-specific effects. Homogeneous overall significant results are drawn as diamonds, effects with significant
heterogeneity are drawn as rectangles, and effects significant in only one sex are drawn as triangles. Metabolites additionally marked by an asterisk are
significant in one sex only and simultaneously show significant heterogeneity. Sex-specificity is further illustrated by a color scale (blue: females; green:
males). On the upper right panel, example boxplots of metabolite residuals (obtained by regressing out included covariates) for each effect type are shown
separately for females and males with (in dark red) and without (in light red) CSF Aβ1–42 pathology, respectively. Source data are provided as Source
Data File.
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metabolites (C8, C10, valine, glycine, and proline) showed het-
erogeneous effects on AD biomarkers in both stratifications. To
investigate the potential additional subgroup-specific effects, we
combined the two stratifications and investigated the selected set
of 21 metabolites for sex-by-APOE ε4 status effect modulations.
Although the group of APOE ε4-carrying women was the smallest
among the four strata (n= 315), all Bonferroni-significant asso-
ciations were found in this subgroup (Table 4): higher levels of
three ether-containing PCs (PC ae C42:4, PC ae C44:5, and PC ae
C44:6) were associated with pathological CSF Aβ1–42, higher
acylcarnitine C10 was associated with higher CSF p-tau, and
higher proline levels were associated with lower FDG-PET values
(Fig. 2). The latter was not observed in any other performed
analysis. In addition, we found significant (PREG < 0.05) interac-
tion effects between all metabolites except C10 and APOE
ε4 status on their associated endophenotypes in females only.
Estimates of effects and effect heterogeneity are stable. To
investigate the robustness of findings reported in this study, we
performed 1000 bootstrap re-samplings for each A-T-N bio-
marker to generate simulated population-based effect distribu-
tions for all significant associations (Supplementary Data 3).
Overall, the difference between effect estimates obtained in the
three rounds of original analyses (pooled sample, onefold, and
twofold stratification) and the respective average effect estimate
across all bootstraps (i.e., the variability by means of estimated
bias) was marginal. We also did not find any instance of an
originally significant association (at PREG ≤ 0.05) where the
bootstrap-t 95% confidence interval contained zero. This means
that the simulated population effect as estimated by boot-
strapping is unequal to zero, suggesting robustness of our
reported findings. Further, 91.97% of simulated effect distribu-
tions were normally distributed (PShapiro-Wilk > 0.05). Boot-
strapping replicated significance of associations at the respective
p value thresholds and the expected (post hoc) power of ≥ 50%
(for details, see Supplementary Data 3) with only three excep-
tions: estimated effect heterogeneity between sexes for the asso-
ciation of valine with pathological CSF Aβ1–42 was, although on
average (i.e., averaged across all 1000 samples) significant, only
significant in 49.9% of bootstraps; the significant associations of
PC ae C44:5 and PC ae C42:4 with pathological CSF Aβ1–42 in
APOE ε4-carrying females on average narrowly missed the
Bonferroni-corrected significance threshold (PREG= 9.45 × 10−4
and PREG= 9.77 × 10−4, respectively), although both metabolites
showed Bonferroni-significant p values in > 50% of bootstraps.
Replication of results in independent cohorts. To the best of our
knowledge, ADNI is currently the only study of AD with data on
Table 3 Association results and heterogeneity estimates for metabolites in relation to A-T-N biomarkers stratified by APOE
ε4 status.
Biomarker/
metabolite
Pooled effect Pooled
p value
Effect type ε4+effect ε4+p value ε4− effect ε4−
p value
ε4 diff.
statistic
ε4 diff.
p value
ε4 diff. I² Interaction
p value
Pathological CSF Aβ1–42
PC ae C44:6 0.283 2.58E-04 Specific to ε4+ 0.630 2.50E-05 0.158 7.96E-02 −2.705 6.83E-03 63.030 2.80E-03
PC ae C44:4 0.265 4.57E-04 Specific to ε4+ 0.565 1.30E-04 0.139 1.13E-01 −2.478 1.32E-02 59.645 5.80E-03
PC ae C44:5 0.260 5.23E-04 Specific to ε4+ 0.609 2.64E-05 0.129 1.37E-01 −2.837 4.56E-03 64.749 3.07E-03
PC ae C42:4 0.242 1.98E-03 Specific to ε4+ 0.564 1.32E-04 0.114 2.15E-01 −2.589 9.61E-03 61.382 5.64E-03
Proline −0.075 3.52E-01 Heterogeneous 0.176 2.15E-01 −0.202 4.40E-02 −2.173 2.98E-02 53.982 1.58E-01
Glycine 0.060 4.60E-01 Heterogeneous 0.363 1.83E-02 −0.102 3.05E-01 −2.538 1.11E-02 60.604 7.89E-04
FDG-PET
PC aa C32:1 −0.127 2.32E-05 Homogeneous −0.087 5.35E-02 −0.162 1.34E-04 −1.210 2.26E-01 17.332 3.58E-01
PC ae C44:4 −0.111 2.27E-04 Homogeneous −0.115 1.39E-02 −0.114 6.34E-03 0.023 9.82E-01 0.000 8.63E-01
PC ae C44:5 −0.105 4.07E-04 Homogeneous −0.122 8.34E-03 −0.102 1.30E-02 0.326 7.44E-01 0.000 6.39E-01
PC aa C32:0 −0.107 6.85E-04 Homogeneous −0.135 4.39E-03 −0.082 6.58E-02 0.818 4.14E-01 0.000 3.69E-01
PC ae C42:4 −0.103 8.56E-04 Homogeneous −0.131 5.79E-03 −0.086 4.51E-02 0.701 4.83E-01 0.000 3.98E-01
C10 −0.057 5.14E-02 Specific to ε4− 0.037 4.17E-01 −0.135 7.17E-04 −2.840 4.51E-03 64.793 4.96E-03
C8 −0.051 9.96E-02 Heterogeneous 0.038 4.04E-01 −0.138 1.58E-03 −2.794 5.20E-03 64.215 6.37E-03
Valine 0.036 2.49E-01 Heterogeneous −0.040 4.08E-01 0.106 1.68E-02 2.234 2.55E-02 55.233 9.50E-02
Glycine −0.032 3.00E-01 Heterogeneous −0.140 3.05E-03 0.059 1.80E-01 3.092 1.99E-03 67.653 3.29E-03
Proline −0.023 4.51E-01 Heterogeneous −0.100 3.39E-02 0.048 2.64E-01 2.324 2.01E-02 56.977 6.35E-02
Associations of metabolites identified in the sex-centric analysis with A-T-N biomarkers that are either Bonferroni-significant in the full sample, in APOE ε4+ or APOE ε4− participants, or show nominal
significance both in one APOE ε4 status group and for effect heterogeneity or the APOE ε4 status×metabolite interaction. Given are regression results for the full sample and both APOE ε4 status groups,
as well as heterogeneity estimates and the p value for APOE ε4 status×metabolite interactions. Full association results for all strata are provided in Supplementary Data 2. ε4 diff. results from the
heterogeneity analysis.
Table 4 Association results and heterogeneity estimates for metabolites in relation to A-T-N biomarkers in APOE ε4 carriers
stratified by sex.
Biomarker/
metabolite
Pooled effect Pooled
p value
Sex diff.
p value
Sex diff. I² ε4 diff.
p value
ε4 diff. I² ε4+ (m)
effect
ε4+ (m)
p value
ε4+ (f)
effect
ε4+ (f)
p value
Pathological CSF Aβ1–42
PC ae C44:6 0.283 2.58E-04 9.15E-01 0.000 6.83E-03 63.03 0.463 1.68E-02 0.922 1.90E-04
PC ae C44:5 0.26 5.23E-04 6.01E-01 0.000 4.56E-03 64.749 0.521 6.17E-03 0.761 8.29E-04
PC ae C42:4 0.242 1.98E-03 7.58E-01 0.000 9.61E-03 61.382 0.42 3.15E-02 0.761 8.65E-04
CSF p-tau
C10 0.084 4.58E-03 2.76E-02 54.613 6.16E-01 0 -0.064 3.24E-01 0.264 1.21E-04
FDG-PET
Proline −0.023 4.51E-01 4.50E-03 64.801 2.01E-02 56.977 0.046 4.76E-01 −0.272 8.22E-05
Significant metabolite effects in the combined stratification (sex by APOE ε4 status) on A-T-N biomarkers are driven by or limited to APOE ε4+ females. Given are regression results for the full sample,
APOE ε4+ males, APOE ε4+ females, as well as heterogeneity estimates by sex and APOE ε4 status. The only metabolite showing effect heterogeneity for both stratification variables was proline in its
association with FDG-PET values. Full association results for all strata are provided in Supplementary Data 2. Sex diff. results from the sex-stratified heterogeneity analysis, ε4 diff. results from the APOE
ε4 status-stratified heterogeneity analysis,ε4+ (m)/ε4+ (f) results for APOE ε4+ males and females, respectively.
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both AD biomarkers and metabolite levels with sufficient sample
sizes to conduct the reported analyses. Estimates of required
sample sizes for replication of our findings are provided in
Supplementary Table 1. We nevertheless sought independent
replication of our results in two other studies with subsets of the
examined variables available: (i) the Rush Religious Order Study
and the Rush Memory and Aging Project (ROS/MAP)56, for
which we had access to 126 and 137 data points with data on
p180 metabolites and data on overall amyloid load and severity of
tau pathology in the brain (based on post-mortem neuropathol-
ogy assessment), respectively (Supplementary Note 1). (ii) the
Australian Imaging, Biomarker & Lifestyle Flagship Study of
Ageing (AIBL) with data on CSF p-tau and comparable mea-
surements of three lipid species (PC ae C36:1, PC ae C36:2, and
SM (OH) C16:1) in 94 participants (Supplementary Note 2). Both
studies had less than one quarter of the mean required sample
size (n= 677).
We were able to replicate all homogeneous associations
reported for pathological CSF Aβ1–42 (PC ae C44:6, PC ae
C44:5, and PC ae C44:4) in ROS/MAP at p values significant after
Bonferroni correction (PREG < 2.94 × 10−3) and with the same
effect directions as in ADNI, despite the different measure for Aβ
pathology. For eight of the 14 sex- and APOE ε4 status-stratified
associations for Aβ and tau pathology, we observed non-zero
effect heterogeneity estimates (I2 of 1.4–45.7%) (Supplementary
Data 4), albeit non-significant. The three metabolite measures in
AIBL all showed non-zero effect heterogeneity estimates (I2 of
39.7–54.3%) in the sex-stratified analyses with CSF p-tau
(Supplementary Data 5), with effect heterogeneity being sig-
nificant for SM (OH) C16:1 (PHET= 0.016). Combined, AIBL and
ROS/MAP yielded non-zero heterogeneity estimates for two out
of four reported group comparisons for Aβ pathology and eight
out of ten reported group comparisons for CSF p-tau and brain
tau pathology.
Discussion
We investigated the influence of sex and APOE ε4 status on
metabolic alterations related to representative A-T-N biomarkers
(CSF Aβ1–42 pathology (A), CSF p-tau (T), FDG-PET (N)). Using
stratified analyses and systematic comparison of the effects esti-
mated for the two sexes, we revealed substantial differences
between men and women in their associations of blood meta-
bolite levels with these AD biomarkers, although known sexual
dimorphisms of peripheral metabolite levels themselves were not
significantly affected by MCI and probable AD status.
Differences between the sexes were largest for associations of
metabolites and CSF p-tau levels. Notably, this biomarker was not
significantly associated with any metabolite when including all
participants and adjusting for both sex and copies of APOE ε4.
However, association analysis stratified by sex (but still adjusted
for copies of APOE ε4) revealed a significant, female-specific
metabolite/CSF p-tau association despite the smaller sample size.
For CSF Aβ1–42 and FDG-PET, in addition to heterogeneous, sex-
specific effects, we also found homogenous effects, in which
metabolite concentrations showed the same trends of metabolite
levels correlating with CSF Aβ1–42 pathology and/or lower brain
glucose uptake in both sexes.
For many of the metabolites with different effects for the sexes,
we additionally observed significant effect heterogeneity between
APOE ε4 carriers and non-carriers, suggesting intertwined
modulation of metabolic effects by sex and APOE genotype.
Indeed, twofold stratification revealed metabolite associations
that were either driven by or specific to the group with pre-
sumably highest risk: APOE ε4-carrying females. Thus, our results
demonstrate the importance of stratified analyses for getting
insights into metabolic underpinnings of AD that are seemingly
restricted to a specific patient group.
The metabolites showing effect heterogeneity across AD bio-
markers in this study highlight sex-specific dysregulations of
energy metabolism (acylcarnitines C2, C5-DC/C6-OH, C8, C10
and C16:1 for lipid-based energy metabolism57; amino acids
valine, glycine, and proline as markers for glucogenic and keto-
genic energy metabolism58–60), energy homeostasis (asparagine,
glycine, proline, and histidine59–63), and (metabolic/nutrient)
stress response (threonine, proline, histidine60,62,64). Although
these pathways have been linked to AD before, our work presents
the first evidence and molecular readouts for sex-related meta-
bolic differences in AD.
For instance, our previous report discussed the implication of
failing lipid energy metabolism in the context of AD biomarker
profiles, starting at the stage of pathological changes in CSF tau
levels45. The current study provides further insights into this
topic, showing this finding to be predominant in females. More
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specifically, we observed a significant female-specific association
of higher levels of acylcarnitine C10 with increased levels of CSF
p-tau, with two other metabolites of this pathway (C8 and C5-
DC/C6-OH) narrowly falling short of meeting the Bonferroni
threshold. This indicates a sex-specific buildup of medium-chain
fatty acids in females, suggesting increased energy demands
coupled with impaired energy production via mitochondrial beta-
oxidation57.
Interestingly, the significant heterogeneity of association shown
by higher levels of glycine being linked to higher levels of CSF p-
tau in men indicates that energy demands are equally upregulated
in males as in females. However, men appear to compensate for
this demand by upregulation of glucose energy metabolism as
glycine is a positive marker of active glucose metabolism and
insulin sensitivity59. Findings for acylcarnitines in females are
further contrasted by the observed male-specific association of
higher levels of the long-chain acylcarnitine C16:1 with decreased
brain glucose uptake, which might indicate that in males there is a
switch to provision of fatty acids as alternative fuel when glucose-
based energy metabolism is less effective. As we did not observe
the buildup of medium- and short-chain acylcarnitines as seen in
females, we assume that, in males, energy production via mito-
chondrial beta-oxidation may be sustained, at least in early
disease.
Evidence corroborating sex-specific processes in energy
homeostasis linked to changes in CSF p-tau levels is provided
by the significantly lower levels of histidine being linked to
higher levels of CSF p-tau in women. Depletion of histidine
is associated with insulin resistance, inflammatory processes,
and oxidative stress, especially in women with metabolic
dysregulation61,62.
We further identified a heterogeneous association of valine
with Aβ1–42 pathology, with lower levels in females (PREG < 0.05),
but not in males. Valine, a BCAA and important energy carrying
molecule, is associated with cognitive decline and brain atrophy
in AD and risk for incident dementia42,45. The lower levels
observed in AD are in contrast to other complex phenotypes such
as type 2 diabetes, insulin resistance, or obesity58,65, in which
higher levels of BCAAs are found, and may indicate a switch to
increased energy consumption via degradation of amino acids in
AD. A recent study reported decreasing levels of valine being
significantly associated with all-cause mortality66. Besides impli-
cations for energy metabolism, results from our study may thus
characterize lower levels of valine also as a marker for increased
female vulnerability to pathogenic processes in general and to β-
amyloidosis in AD in particular.
To elaborate on potential interrelated risk predispositions via
sex and APOE ε4 genotype from a metabolomics point of view,
we further investigated whether APOE ε4 status may also mod-
ulate metabolic readouts of AD-linked A-T-N biomarker profiles
identified in sex-centered analyses. Indeed, the majority (68.8%)
of observed associations between metabolites and AD biomarkers
showed significant heterogeneity between APOE ε4 status groups.
Notably, the full set of metabolites yielding significant effect
heterogeneity when comparing APOE ε4 carriers vs. non-carriers
(C8, C10, glycine, proline, and valine) showed significant het-
erogeneity estimates in the sex-stratified analyses. We therefore
applied twofold stratification by sex and APOE ε4 status to
identify potential interactions between both variables (Supple-
mentary Fig. 4). Several associations showed Bonferroni sig-
nificance in the group with presumably the highest AD risk:
APOE ε4+ females. One of the significant associations—higher
proline levels with reduced brain glucose uptake—was not
observed in the three other strata, the onefold stratifications, or
the full sample, emphasizing the value of more fine-granular
stratified analyses as proposed here.
The heterogeneity of metabolite effects as identified in this
study might, in part, explain inconsistencies (e.g., ref. 67 vs. ref. 68)
in associations of metabolites and AD reported in other studies
(e.g., if sex and APOE genotype are distributed differently and
sample sizes are small). In contrast, the homogeneous effects
reported in our study may represent more generic metabolic
hallmarks in AD. For instance, PCs that presumably contain two
long-chain fatty acids with, in total, four or five double bonds (PC
ae C44:4, PC ae C44:5) were significantly associated with both
CSF Aβ1–42 and FDG-PET, showing homogeneous effects in
males and females. These associations should be less sensitive to
balancing of group sizes and replicate well across studies.
To test this assumption in an independent sample, we per-
formed a targeted analysis using the three PCs homogeneously
(PC ae C44:4, PC ae C44:5, PC ae C44:6) associated with CSF
Aβ1–42 pathology in 126 serum samples of 86 participants in the
ROS/MAP cohorts (Supplementary Note 2). All three associa-
tions were Bonferroni significant with consistent effect directions,
although we used a different measure of amyloid pathology as a
proxy, namely total amyloid load in the brain, which is inversely
correlated with CSF Aβ1–42 levels69. This inverse relationship was
mirrored by metabolite effect estimates. These results provide
evidence for homogeneous associations to be relevant across
cohorts.
There are several limitations to this study. First, the reported
findings are observational and do not allow for direct causal
conclusions. Second, the reported heterogeneity estimates still
await replication in an independent cohort with sample sizes
appropriate for stratification as well as metabolomics and endo-
phenotypic data available. Available sample sizes in ROS/MAP
and AIBL were too small to be sufficiently powered. Furthermore,
ROS/MAP samples were poorly balanced for both sex (73%
females) and APOE ε4 status (77% APOE ε4−), leading to even
more limited power in the stratified analyses. Third, stratified
analyses in combination with heterogeneity estimates may iden-
tify spurious associations, primarily due to the limited power
resulting from group separation. However, bootstrapping analysis
indicated overall robustness of our findings. In addition, we
showed that for the majority of the non-homogeneous findings
reported (60%), the interaction terms between metabolite levels
and sex were also significant in the pooled analysis. When stra-
tifying by APOE ε4 status, this was true for an even higher
fraction of cases (72.7%). In conjunction with 71.4% of investi-
gated effects showing non-zero heterogeneity in AIBL or ROS/
MAP, this provides an additional line of support for the con-
clusions drawn in this work. Finally, we only investigated two AD
risk factors using a limited metabolomics panel focused on
lipid and amino acid metabolism. Further risk factors, such as
type 2 diabetes, cardiovascular disease, and high blood pressure,
are linked to metabolic aspects as well and may reveal even
greater molecular heterogeneity, in particular, when expanding to
additional metabolic pathways, e.g., by using non-targeted
metabolomics.
In conclusion, effect heterogeneity between subgroups linked
to energy metabolism reported in the present study has several
important implications for AD research. First, this heterogeneity
could explain inconsistencies of metabolomics findings between
studies as observed for AD if participants showed different dis-
tributions of variables such as sex and APOE ε4 genotype. Second,
pooled analysis with model adjustment for such variables, as
typically applied for sex, can mask substantial effects that are
relevant for only a subgroup of people. This is also true for
combinations of stratifying variables as we demonstrated for the
association of proline with brain glucose uptake in female APOE
ε4 carriers. Consequently, drug trials may have more success by
acknowledging between-group differences and targeting the
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subgroup with the presumably largest benefit in their inclusion
criteria. For energy metabolism, group-specific dietary interven-
tions precisely targeting the respective dysfunctional pathways
may pose a promising alternative to de novo drug development.
Extending our approach by selection of additional variables to
further improve stratification may eventually guide the way to
precision medicine.
Methods
Study participants. Data used in the preparation of this article were obtained from
the ADNI database (http://adni.loni.usc.edu/). The ADNI was launched in 2003 as
a public-private partnership. The primary goal of ADNI has been to test whether
serial magnetic resonance imaging, PET, other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of
MCI and early AD. For up-to-date information, see www.adni-info.org. Written
informed consent was obtained at enrollment, which included permission for
analysis and data sharing. Consent forms were approved by each participating site’s
institutional review board. Metabolomics data and results have been made acces-
sible through the AMP-AD Knowledge Portal (https://ampadportal.org). The
AMP-AD Knowledge Portal is the distribution site for data, analysis results, ana-
lytical methodology, and research tools generated by the AMP-AD Target Dis-
covery and Preclinical Validation Consortium and multiple Consortia and research
programs supported by the National Institute on Aging. Information on data
availability and accessibility is available in the Data availability section.
We included 1517 baseline serum samples of fasting participants pooled from
ADNI phases 1, GO, and 2. Demographics, diagnostic groups, and numbers and
distributions of key risk factors are provided in Table 1. AD dementia diagnosis
was established based on the NINDS-ADRDA criteria for probable AD for
individuals with Mini-Mental State Exam (MMSE) scores between 20 and 26
(inclusive) and a Clinical Dementia Rating Scale (CDR) of 0.5 or 1.0. MCI
participants did not meet these AD criteria and had MMSE scores between 24 and
30 (inclusive), a memory complaint, objective memory loss measured by
education-adjusted scores on Wechsler Memory Scale Logical Memory II, a CDR
of 0.5, absence of significant levels of impairment in other cognitive domains, and
essentially preserved activities of daily living, meeting predetermined criteria for
amnestic MCI70. Of the 1517 participants, 689 were female and 828 male, with 708
APOE ε4 carriers and 809 non-carriers. In the combined stratification by sex
and APOE ε4 status (APOE ε4−= 0 copies of ε4, APOE ε4+= 1 or 2 copies of ε4),
the APOE ε4 non-carriers were separated into 374 females and 435 males, whereas
of APOE ε4 carriers 315 were female and 393 male.
Metabolomics data acquisition. Metabolites were measured with the targeted
AbsoluteIDQ-p180 metabolomics kit (BIOCRATES Life Science AG, Innsbruck,
Austria), with an ultra-performance liquid chromatography tandem mass spec-
trometry (MS/MS) system (Acquity UPLC (Waters), TQ-S triple quadrupole MS/
MS (Waters)), which provides measurements of up to 186 endogenous metabolites.
Sample extraction, metabolite measurement, identification, quantification, and
primary quality control (QC) followed standard procedures45,71.
Metabolomics data processing. Metabolomics data processing followed pub-
lished protocols45,71 with a few adjustments. Raw metabolomics data for 182
metabolites was available for serum study samples of 1681 participants (four
metabolites were removed owing to technical issues during measurement) mea-
sured on 23 plates. For each plate, 2–3 NIST Standard Reference samples were
available. Furthermore, we also had blinded duplicated measurements for 19 sam-
ples (ADNI-1) and blinded triplicated measurements for 17 samples (ADNI-GO
and -2) distributed across plates. We first excluded 23 metabolites with large
numbers of missing values (>20%). Then, we removed plate batch effects applying
cross-plate mean normalization using NIST metabolite concentrations (Supple-
mentary Fig. 5). Duplicated and triplicated study samples were then utilized to
calculate the coefficients of variation (exclusion criterion > 20%) and intra-class
correlation (exclusion criterion < 65%) for each metabolite. We removed 20
metabolites that violated these thresholds. Next, we average-combined biological
replicates and excluded non-fasting participants (n= 108), imputed missing
metabolite data using half the value of the lower limit of detection per metabolite
and plate, log2-transformed metabolite concentrations, centered and scaled dis-
tributions to a mean of zero and unit variance and winsorized single outlying
values to three standard deviations. We then used the Mahalanobis distance for
detection of multivariate subject outliers, applying the critical Chi-square value for
P < 0.01 and removing 42 participants. Finally, metabolites were adjusted for sig-
nificant medication effects using stepwise backwards selection (for details, see
ref. 71). The final QC-ed metabolomics data set was further restricted to individuals
with data on all significant covariates (see section Phenotype data and covariate
selection), resulting in the study data set of 139 metabolites and 1517 individuals.
Derived quality control measures for all metabolites are provided in Supplementary
Data 6, and their distributions after QC are provided in Supplementary Fig. 6.
Phenotype data and covariate selection. We limited association analyses of
metabolites with AD to early detectable endophenotypes, specifically to the
pathological threshold for CSF Aβ1–42, levels of phosphorylated tau protein in the
CSF (p-tau), and brain glucose metabolism measured by FDG-PET. Baseline data
on these biomarkers for ADNI-1, -GO, and -2 participants were downloaded from
the LONI online portal at https://ida.loni.usc.edu/. For CSF biomarker data, we
used the data set generated using the validated and highly automated Roche Elecsys
electrochemiluminescence immunoassays72,73. For FDG-PET, we used an ROI-
based measure of average glucose uptake across the left and right angular, left and
right temporal, and bilateral posterior cingulate regions derived from preprocessed
scans (co-registered, averaged, standardized image and voxel size, uniform reso-
lution) and intensity-normalized using a pons ROI to obtain standard uptake value
ratio means74,75. The pathological CSF Aβ1–42 cut-point (1073 pg/ml) as reported
by the ADNI biomarker core for diagnosis-independent mixture modeling (see
http://adni.loni.usc.edu/methods/, accessed Oct 2017) was used for categorization,
as CSF Aβ1–42 concentrations were not normally distributed. Processed FDG-PET
values were scaled and centered to zero mean and unit variance prior to association
analysis, p-tau levels were additionally log2-transformed. We extracted covariates
including age, sex, BMI (calculated using baseline weight and body height), number
of copies of the APOE ε4 genotype, and years of education. Covariates were
separated into forced-in covariates (age, sex, ADNI study phase, and number of
copies of APOE ε4) and covariates (BMI, education) selectable by backwards
selection. ADNI study phase was included to adjust for remaining metabolic dif-
ferences between batches (ADNI-1 and ADNI-GO/-2 were processed in separate
runs) and differences in PET imaging technologies.
Association analyses. Association analyses of the three AD biomarkers with
metabolite levels were conducted using standard linear (p-tau, FDG-PET) and
logistic (pathological Aβ1–42) regression. For pathological CSF Aβ1–42, only BMI
was additionally selected; for p-tau and FDG-PET, the full set of covariates was
used. The stratification variables sex and copies of APOE ε4 were excluded as
covariates in the sex-stratified and APOE ε4+/− status-stratified analyses,
respectively. For identifying metabolic sex differences, we used linear regression
with metabolite levels as the dependent variable and age, sex, BMI, ADNI study
phase, and diagnostic group as explanatory variables and retrieved statistics for sex.
To adjust for multiple testing, we accounted for the significant correlation structure
across the 139 metabolites using the method of Li and Ji76 and determined the
number of independent metabolic features (i.e., tests) to be 55, leading to a
threshold of Bonferroni significance of 9.09 × 10−4. To assess significance of het-
erogeneity between strata, we used the methodology of25,77 that is similar to the
determination of study heterogeneity in inverse-weighted meta-analysis. We fur-
ther provide a scaled (0–100%) index of percent heterogeneity similar to the I2
statistic78.
Bootstrapping analysis. Bootstrapping was performed using ordinary nonpara-
metric bootstraps for each of the three A-T-N biomarkers separately. For this, we
drew random indices with replacement a 1000 times from all participants in ADNI
with the biomarker available. Association analysis was performed on each boot-
strap using the same regression models as described above. We then calculated the
bias of the effect estimates (i.e., the difference between effect estimates obtained in
the original analyses and the respective average effect estimate across all boot-
straps), as well as the bootstrap-t (or studentized) 95% confidence interval that is
taking into account the variance of the estimates in each single bootstrap. Averaged
bootstrap statistics were obtained using the mean of the beta estimates and the
mean of their standard errors across the set of 1000 bootstraps and using their ratio
as statistic to retrieve associated two-tailed p values from the standard normal
distribution.
Power analysis. In each power analysis, we transformed covariate-adjusted effect
sizes to sample size-weighted standardized effects (Cohen’s d). For metabolic sex
differences, we calculated the power for two-sample t tests to identify significant
sexual dimorphisms for metabolites with the standardized effect sizes observed in
the pooled ADNI samples at Bonferroni significance in CN participants, partici-
pants with MCI, and patients with probable AD. To obtain estimates of sample
sizes required to replicate metabolite associations and heterogeneity estimates, we
used the same approach with power fixed to 50% (the post hoc/observed power to
find results at p values equal or below the respective applied threshold, i.e., nominal
or Bonferroni significance). Thereby, we estimated sample sizes assuming perfectly
balanced data sets (with respect to sex and APOE ε4 status). This is a very rough
approximation as it further assumes that the effect sizes reported for ADNI are
generalizable to any replication cohort. Therefore, reported required sample sizes
may deviate in reality.
Replication analysis in ROS/MAP and AIBL. The ROS/MAP studies are both
longitudinal cohort studies of aging and AD at Rush University56 and are designed
to be used in joint analyses to maximize sample size. Both studies were approved by
an Institutional Review Board of Rush University Medical Center. All participants
signed an informed consent and a repository consent to allow their biospecimens
and data to be used for ancillary studies. We measured metabolite levels using the
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AbsoluteIDQ-p180 metabolomics kit in 596 serum samples from 559 participants
(37 additional samples from follow-up visits). Brain amyloid pathology data were
available for 89 participants (126 serum samples) comprised of 40 CN, 28 MCI,
and 21 AD participants; 100 participants (137 serum samples) had brain tau
pathology data (46 CN, 28 MCI, and 26 AD). Key demographic characteristics of
ROS/MAP cohorts and information on data acquisition and processing are pro-
vided in Supplementary Note 1. To obtain maximal power for replication, we
included longitudinal metabolomics data where available and applied linear mixed
models for association analysis. We used the same covariates as in ADNI, including
study phase (ROS or MAP), sex, age at visit, BMI, copies of APOE ε4, and edu-
cation (only for tau pathology). Race was added as additional covariate. Random
effects (intercept) in the mixed models were included for both visit and participant
identifiers.
AIBL is a longitudinal study of over 1100 people assessed over > 4.5 years to
determine which biomarkers, cognitive characteristics, and health and lifestyle
factors determine subsequent development of symptomatic AD. The AIBL study
was approved by the institutional ethics committees of Austin Health, St. Vincent’s
Health, Hollywood Private Hospital and Edith Cowan University, and all
volunteers gave written informed consent before participating in the study. We had
access to measurements of CSF p-tau for 94 participants (82 CN, 7 MCI, and 5 AD)
with lipidomic data available. In contrast to ADNI, lipidomic data in AIBL was
assessed on the UHPLC-MS/MS platform of the Metabolomics Laboratory of the
Baker Heart and Diabetes Institute, Melbourne, Australia, and not the
AbsoluteIDQ-p180 metabolomics kit. As a consequence, matching measures of
only three metabolites (PC ae C36:1, PC ae C36:2, and SM (OH) C16:1) could be
derived in AIBL and were available for replication. Details on the matching process,
as well as key demographic characteristics of AIBL participants and information on
data acquisition and processing are provided in Supplementary Note 2. Association
analysis was performed for log-transformed CSF p-tau levels and the three
metabolite measures using linear regression while adjusting for sex, age, BMI,
APOE ε4 status, and education. For both ROS/MAP and AIBL, sex and APOE ε4,
respectively, were omitted as covariates in stratified analyses and heterogeneity
estimates were calculated as in ADNI.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Metabolomics data sets from the AbsoluteIDQ-p180 metabolomics kit used in the
current analyses for the ADNI-1, ADNI-GO/-2, and ROS/MAP cohorts are available via
the Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD) Knowledge
Portal (https://doi.org/10.7303/syn2580853) and can be accessed at https://doi.org/
10.7303/syn5592519 (ADNI-1), https://doi.org/10.7303/syn9705278 (ADNI-GO/-2), and
https://doi.org/10.7303/syn10235592 (ROS/MAP). The full complement of clinical and
demographic data for the ADNI cohorts are hosted on the LONI data sharing platform
and can be requested at http://adni.loni.usc.edu/data-samples/access-data/. The full
complement of clinical and demographic data for the ROS/MAP cohorts are available via
the Rush AD Center Resource Sharing Hub and can be requested at https://www.radc.
rush.edu. AIBL data are available upon request at https://aibl.csiro.au. Source data are
provided as Source Data File.
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